Danaher Corporation 10-Q Summary
Business Context and Reporting Period
This filing is a Quarterly Report (Form 10-Q) for Danaher Corporation for the three-month period ended April 2, 2004. Danaher designs, manufactures, and markets industrial and consumer products across two primary segments: Process/Environmental Controls and Tools and Components. The quarter was characterized by significant acquisition activity, including the purchase of Radiometer A/S and the formation of a new Medical Technology platform.
Key Financial Metrics
| Metric | Q1 2004 | Q1 2003 |
|---|---|---|
| Sales | $1,543.2 million | $1,196.2 million |
| Net Earnings | $145.2 million | $103.1 million |
| Diluted EPS | $0.90 | $0.65 |
| Operating Profit | $225.0 million | $167.0 million |
| Gross Margin | 40.9% | 39.1% |
| Operating Cash Flow | $251.9 million | $214.3 million |
| Cash & Equivalents (Ending) | $642.5 million | $911.6 million |
| Total Debt | $1,341.7 million | $1,298.9 million |
Material Changes vs. Prior Period
- Revenue Growth: Sales increased 29% year-over-year. This growth was driven by 12.5% organic growth from existing businesses, 12% from acquisitions, and 4.5% from favorable currency translation (primarily Euro strength). The 2004 quarter also included three additional business days compared to 2003, contributing an estimated 4.5% to sales growth.
- Profitability: Operating profit rose 35% to $225.0 million. Gross margins improved to 40.9% due to sales leverage, cost reduction initiatives (Danaher Business System), and the inclusion of higher-margin acquired businesses like Radiometer.
- Acquisitions: The company spent approximately $814 million in cash on four acquisitions in Q1 2004, most notably Radiometer A/S ($677 million net cash). This significantly reduced cash balances from $1.23 billion at year-end 2003 to $642 million.
- Segment Performance:
- Process/Environmental Controls: Sales up 32% to $1.23 billion; Operating profit up 36% to $187.2 million.
- Tools and Components: Sales up 18% to $316.8 million; Operating profit up 29% to $44.6 million.
Guidance, Outlook, and Risks
- Outlook: Management expects the strength seen in late 2003 and Q1 2004 to continue in the near term. Gross margins are expected to improve further in 2004 due to the Medical Technology platform. The effective tax rate is projected to decline to 30.0% or less for the remainder of 2004 following organizational realignments.
- Pending Acquisition: In March 2004, Danaher signed an agreement to acquire Kaltenbach & Voigt GmbH (KaVo) for approximately $425 million. Closing is expected in Q2 2004.
- Liquidity: The company holds $642 million in cash. While sufficient for current operations, the pending KaVo acquisition will reduce available cash by approximately $425 million. The company maintains $1 billion in revolving credit facilities, none of which were drawn upon during the period.
- Risks: Key risks include currency exchange rate fluctuations (though the company generally accepts this exposure), integration risks of acquired businesses, raw material cost increases (specifically steel), and global economic conditions.
Investor Verification Checklist
- Acquisition Integration: Verify the successful integration of Radiometer and the pending KaVo deal, as these are central to the new Medical Technology platform strategy.
- Currency Impact: Monitor the Euro/USD exchange rate, as favorable translation significantly boosted Q1 results and future results may vary if the dollar strengthens.
- Working Capital: Review the sustainability of the 17.5% increase in operating cash flow, which was partly driven by increased vendor payables.
- Debt Structure: Note the $556.9 million in zero-coupon convertible notes (LYONs) and the $364.1 million in Eurobond notes; monitor interest rate sensitivity and potential conversion triggers.
- Restructuring Costs: Track the utilization of accrued liabilities for employee terminations and facility closures related to recent acquisitions ($20.5 million and $24.8 million respectively as of April 2, 2004).